ClinicalTrials.gg
Status unknownNCT04290325Updated Jun 16, 2020

HMPL-453 in Advanced Malignant Mesothelioma

A Phase 2 interventional study of HMPL-453 in Advanced Malignant Mesothelioma, sponsored by Hutchison Medipharma Limited. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-16.

Sponsored by Hutchison Medipharma Limited (part of HUTCHMED) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Mesothelioma, Malignant with a site in China — 11 open to participants now, 13 under way, 1 of them phase 3. Mesothelioma, Malignant · China.

Planned enrollment
13th of 18
27 · median 37
Started
2019
with 2 others
Phase 2
4 of 20
2 open now
Registered
5th of 20
by date

Among the 20 studies in Mesothelioma, Malignant with a site in China, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2019, is one of 4 in phase 2, and was the 5th registered.

Mesothelioma, Malignant

339 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.

Browse Mesothelioma, Malignant studies →

Open to participants now

11 of the 20 studies in Mesothelioma, Malignant with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Mesothelioma, Malignant studies recruiting now, 42 (78%) set no upper age limit and 5 (9%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Mesothelioma, Malignant with a site in China, or all of them as a file.
02

Study summary

This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 in patient with advanced Malignant Mesothelioma

Read the detailed description

Histologically confirmed patients with advanced malignant mesothelioma that who was failure of the first -line systemic therapy

03

Conditions studied

  • Advanced Malignant Mesothelioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Signed written ;
  • 2.18 years of age or older;
  • 3. diagnosed malignant mesothelioma (including pleura, peritoneum, pericardium, and testicular tendon sheath origin, cell type epithelioid, sarcoma-like, or mixed type), and cannot be cured radically;
  • 4.Received one to three regimen of prior systemic therapy and then experienced documented radiographic progression or intolerable toxicity;
  • 5.Patients agreed to provide tumor tissue for FGF/FGFR testing;
  • 6. by version 1.1 criteria;
  • 7. performance status ≤ 2.;

Exclusion criteria

Exclusion Criteria:

  • 1.Previous treatment with any FGFR inhibitor;
  • 2.Received systemic anti-cancer therapy within 3 weeks of the first dose of HMPL-453;
  • 3.Major surgery within 4 weeks of the first dose of HMPL-453;
  • 4.Use of a strong inducer or inhibitor of cytochrome P450 3A4 () within 1 week of the first dose of HMPL-453;
  • 5.Inadequate conditions as indicated by the following laboratory values:

    • (ANC)\<1.5 x 109/L
    • \< 80 g/L
    • count \<80 x 109/L
  • 6.Any of the following conditions of liver and kidney insufficiency:

    • Total > 1.5 x
    • and ALT > 2.5 x ULN (> 5 x ULN for patients with liver )
    • of \< 50 mL/min as estimated by the Cockcroft-Gault equation
  • 7. (INR) >1.5 or activated partial thromboplastin time (aPTT) >1.5 x ULN;
  • 8.Clinical significant liver disease;
  • 9.Known (HIV) infection
  • 10.Previous history of retinal detachment;
  • 11.Unable to swallow the study drug.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    HMPL-453

    HMPL-453

    Drug: HMPL-453

Interventions

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    Evaluating ORR of HMPL-453 in patient with advanced malignant mesothelioma

    Time frame: measured up to 6 months after the last subject has been enrolled or all subjects have finished their last PFS follow up, whichever comes first

Secondary outcomes

  1. Disease control rate (DCR)

    Evaluating DCR of HMPL-453 in patient with advanced malignant mesothelioma

    Time frame: measured up to 6 months after the last subject has been enrolled or all subjects have finished their last PFS follow up, whichever comes first

  2. 12 weeks DCR

    Evaluating 12 weeks DCR of HMPL-453 in patient with advanced malignant mesothelioma

    Time frame: measured on 12 weeks

  3. Time to Response (TTR)

    Evaluating TTR of HMPL-453 in patient who achieved partial response or complete response according to RECIST 1.1 or mRECIST 1.1

    Time frame: measured on 4 weeks

  4. Duration of response (DoR)

    Evaluating DoR of HMPL-453 in patient from subject first achieve a complete remission, or partial remission to patient PD, or death whichever comes first.

    Time frame: measured on 30 weeks

  5. 12 weeks PFS

    Evaluating 12 weeks PFS rate of HMPL-453 in patient with advanced malignant mesothelioma

    Time frame: measured on 12 weeks

  6. Progression free survival (PFS)

    Evaluating PFS of HMPL-453 in patient with advanced malignant mesothelioma.

    Time frame: measured on 20 weeks

  7. Overall survival (OS)

    Evaluating OS of HMPL-453 in patient with advanced malignant mesothelioma

    Time frame: measured on 60weeks

  8. Adverse Event (AE) of HMPL-453 monitoring

    The safety endpoints include adverse events (AEs) and serious adverse events (SAEs). Reporting of safety, extent of exposure, concomitant medications and discontinuation of study therapy will be based on all subjects who received at least 1 dose of treatment. The adverse events will be registered according to NCI CTCAE 5.0.

    Time frame: Measured from the first dose to within 30 days after the end of treatment.

  9. Maximum plasma concentration (Cmax) of HMPL-453

    Evaluating Cmax of Continuous dosing of HMPL-453 in patient with advanced malignant

    Time frame: measured on Cycle 1 day 15 and day 16

  10. The time to Cmax (Tmax) of HMPL-453

    Evaluating Tmax of Continuous dosing of HMPL-453 in patient with advanced malignant

    Time frame: measured on Cycle 1 day 15 and day 16

  11. The area under the plasma concentration-time curve (AUC) of HMPL-453

    Evaluating AUC from 0 to the time of the last measurable concentration of HMPL-453 in patient with advanced malignant

    Time frame: measured on Cycle 1 day 15 and day 16

07

Study locations

1 of 1 sites recruiting
  • Shanghai Chest Hospital
    Shanghai, 21000, China
    Recruiting
    • Shun Lu, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Nov 2022, 35 months after the start.

Of 48 phase 2 interventional studies under Mesothelioma, Malignant, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2020
First posted
Feb 28, 2020
StartActual
Dec 30, 2019
Primary completionEst.
Nov 30, 2022
CompletionEst.
Mar 17, 2023
Last update
Jun 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04290325
Responsible party
Sponsor
First posted
Feb 28, 2020
Start date
Dec 30, 2019
Primary completion
Nov 30, 2022 (estimated)
Completion
Mar 17, 2023 (estimated)
Last update
Jun 16, 2020

Study contacts

Wenjuan Ding
Contact
Wenjuand@hmplglobal.com
+8602120671806 ext. +8602120671806
Chen Yu
Contact
Cheny@hmplglobal.com
Shun Lu, Prof.
principal investigator · Shanghai Chest Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fanregratinib

Start the discussion